HUBRO BIOSCIENCE AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: JA
Jon Amund Eriksen1954
Chairman of the board: JA
Jon Amund Eriksen1954
Years since formation: 1 year; since May 21, 2024
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 30,000; 1 share class
Total number of shareholders: 2; companies
Belongs to group of

Last update: Jan 9, 2025

Management

Management / administration

Name	Role	Shares
JA Jon Amund Eriksen 1954	Managing Director/CEO	40 % indirectly

Board

Name	Role	Shares
JA Jon Amund Eriksen 1954	Chairman	40 % indirectly
TA Tom Arne Thorsen 1967	Deputy Chair	60 % indirectly
RM Robert Matthew Miller 1952	Board Member	-

Others

Name	Role	Shares
A AMESTO ACCOUNTHOUSE AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
TA Tom Arne Thorsen 1967	Deputy Chair	60 % indirectly
JA Jon Amund Eriksen 1954	Managing Director/CEO, Chairman	40 % indirectly

Last update: Aug 23, 2024

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
A ALGOT INVEST AS	Ordinary shares	18,000	60 %
T TIMMUNO AS	Ordinary shares	12,000	40 %

Last update: Jun 2, 2025

Group structure

ALGOT INVEST AS
Total operating income 2023: NOK 0
Operating profit 2023: NOK -107,854
Employees: 0

Financials

in NOK

No available data

HUBRO BIOSCIENCE AS933 476 561